Medical Research News
Focus on the latest clinical studies, reports, findings, programs and standards covering a wide spectrum of medical and health issues. This section highlights research into human populations and includes information about research facilities, funding, resources and public policy.
National Sleep Awareness Week 2026: Pennington Biomedical’s Dr. Prachi Singh Shares Importance of a Complete Night’s Rest
A critical component of health, sleep can improve memory, promote brain health, strengthen the immune system and more. - March 12, 2026 - Pennington Biomedical Research Center
Pennington Biomedical Researcher Publishes Editorial in Leading American Heart Association Journal
Food is Medicine: Dr. John Apolzan highlights the importance of fruit intake on vascular health. - March 11, 2026 - Pennington Biomedical Research Center
Hemanext ONE® Receives 510(k) Clearance for Expanded Indications for Use in the United States
Hemanext Inc. today announced that the Hemanext ONE® System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded indications for use in the United States. The expanded Indications for Use enable processing of whole blood and apheresis-derived AS-3 leukocyte-reduced red blood cells. - March 10, 2026 - Hemanext
Shane Ray Appointed as President and Chief Executive Officer of Hemanext
Hemanext Inc., a leading innovator in blood processing, storage and transfusion technology, is pleased to announce that the Board has appointed Shane Ray to take on the role of President and Chief Executive Officer of Hemanext from Andy Dunham. Shane will also retain his role as the Chief Commercial Officer to lead the global commercial strategy and sales team while Andy will remain on the Executive Leadership Team as Hemanext’s Chief Scientific Officer. - February 24, 2026 - Hemanext
Saratoga Medical Center Evolves Into Saratoga Ascend, Marking a New Era of Growth
Saratoga Medical Center announces the national expansion of its DBA, Saratoga Ascend, delivering integrated healthcare, IT, and life sciences solutions and staffing services to federal, state, and military agencies across the United States. - February 04, 2026 - Saratoga Ascend
Evolve Medical Announces the Launch of a New Mental Wellness Technology - EXOMIND™
Evolve Medical announces the launch of EXOMIND™, a non-invasive mental wellness technology using FDA-cleared transcranial magnetic stimulation (TMS) to support cognitive performance and emotional wellbeing. Drug-free and requiring no downtime, EXOMIND™ leverages neuroplasticity to enhance mood, focus, and mental clarity as part of Evolve Medical’s holistic, science-based approach to brain health. - January 20, 2026 - Evolve Medical
Dr. Elizabeth Stanley Named Associate Executive Director of Operations at Pennington Biomedical Research Center
Stanley replaced long-time AED of Operations Guy LaVergne - January 14, 2026 - Pennington Biomedical Research Center
CanVeer Biopharma Launches Validation Program for Flagship Neonatal Therapeutic and Appoints Executive Team
CanVeer announces the launch of the validation program for its flagship product, AlveoShield™ (Investigational New Drug). The program targets preterm newborns with or at risk of developing bronchopulmonary dysplasia (BPD). Bronchopulmonary dysplasia is a chronic respiratory disease affecting preterm neonates who require assisted ventilation. AlveoShield™ is designed to potentially prevent and treat BPD. CanVeer also announces the appointment of Sherif Louis as CEO and Behzad Yeganeh as CSO. - January 13, 2026 - CanVeer Biopharma Inc.
Accomplishments and Expansion of the Institute of Dementia Research & Prevention Highlighted at LSU Board of Supervisors Meeting
Web LABrainS has potential to engage more than 20,000 participants, adding assessments of sleep, driving risk, and falls, and integrating caregiver offerings that connect families to services and research opportunities. - January 11, 2026 - Pennington Biomedical Research Center
Researchers Show Visual Training Dramatically Improves Cognitive Function After Concussion
Study shows new approach restores attention, memory and reading skills faster than standard therapies A new peer-reviewed study led by scientists at the Perception Dynamics Institute and the University of California San Diego demonstrates that a specific visual training program significantly... - December 15, 2025 - Perception Dynamics Institute
Pennington Biomedical Makes History with First-Ever International Symposium in Riyadh
Pennington Biomedical recognizes the pivotal contributions of Center researchers who presented and reprensted the Center during the symposium Dr. John Kirwan, Dr. Phil Schauer and Dr. Donna Ryan. - December 11, 2025 - Pennington Biomedical Research Center
Dr. Gordin, Partner of mytsv.com, Unveils Transformative 2-Hour Holistic Intake Method for Health
Dr. Gordin, a leading practitioner dedicated to achieving better health results, is challenging the industry standard of rapid consultations with his commitment to in-depth listening and comprehensive patient analysis. - December 10, 2025 - MyTSV.com
iFyber Expands Analytical Capabilities with Launch of Advanced LC-MS Services
iFyber has expanded its LC-MS analytical capabilities with advanced Orbitrap and UHPLC technology and the addition of industry experts Gary Schultz, PhD, and Brian Hoffman. The enhanced platform boosts sensitivity and analytical depth, supporting proteomics, metabolomics, E&L, and contaminant testing, strengthening iFyber’s mission to deliver high-quality, decision-driving preclinical insights. - December 10, 2025 - iFyber
New York Cancer & Blood Specialists Launches State's First Personalized Nutrition Care Program for Cancer Patients
Cancer treatment has achieved molecular precision. Yet one fundamental barrier remains: keeping patients strong enough to complete the therapies oncologists prescribe. Up to half of cancer patients experience severe malnutrition, leading to more side effects, treatment delays, and poorer... - December 04, 2025 - New York Cancer & Blood Specialists
NatureQuant® Awarded Patent for NatureScore® and NatureDose® AI-Powered Environmental Impact Measurement Model
NatureQuant’s foundation technologies analyze environmental and personal data to unlock actionable nature exposure intelligence. - November 25, 2025 - NatureQuant
Eminent Spine’s 3D Printed Titanium Posterior SI System Receives FDA 510(k) Clearance
Eminent Spine's 3D Printed Titanium posterior SI system compresses and transfixes the SI joint. - November 12, 2025 - Eminent Spine
Alera Bio Announces Appointment of Board of Directors
Alera Bio, a Chicago-based biotech developing therapies for rare neuroendocrine and neurological disorders, announced its inaugural Board of Directors. The board includes leaders in biopharma, clinical practice, and finance, such as Stephen Hill, Mark Prygocki, Renny Griffith, and Cassius Coleman. Their combined expertise will guide Alera Bio as it advances AB-101 for MCT-8 deficiency, an FDA-designated Rare Pediatric Disease therapy. - November 11, 2025 - Alera Bio
Immundiagnostik, Inc. Partners With Epitope Diagnostics, Inc. to Offer Chemiluminescent Solutions
A new partnership between Immundiagnostik, Inc. and Epitope Diagnostics, Inc. expands access to innovative solutions, enhancing efficiency and accuracy for clinical and research labs. - October 22, 2025 - Immundiagnostik, Inc.
New Study Shows Self-Guided Online Exercise Program Significantly Improves Strength and Reduces Fall Risk in Midlife and Older Women
A new study to be presented at The Menopause Society (TMS) 2025 Annual Meeting by Osteoboost Health shows that a self-guided, online exercise program led to rapid and clinically meaningful improvements in leg strength and endurance — key factors in reducing fall risk — in women ages 40... - October 21, 2025 - Osteoboost Health
Pennington Biomedical Hosts NIDDK Clinical Methods for Nutrition & Obesity Research Course for Postdoctoral Fellows
Intensive four-day training program designed to equip postdoctoral fellows, advanced doctoral students, and early career investigators with hands-on expertise in state-of-the-art methods for clinical research in obesity, metabolism and nutrition - October 17, 2025 - Pennington Biomedical Research Center
New Report Uncovers What Sponsors Really Think About Preclinical Services and CROs
Life Science Strategy Group’s Preclinical Services Landscape and CRO Benchmarking Assessment Delivers Data-Driven Insights on Budgets, Outsourcing, Vendor Preferences, and Industry Shifts - October 16, 2025 - Life Science Strategy Group, LLC
Hemanext Inc. Awarded $2.9M NIH Grant to Advance Clinical Initiatives in the United States
Hemanext Inc has been awarded a three-year Small Business Innovation Research Grant (SBIR) Phase II for a project titled, “Efficacy of Hypoxic Red Blood Cells Processed with the Hemanext ONE® System in Patients with Sickle Cell Anemia,” to support and strengthen the clinical efforts of hypoxically stored red blood cells (HRBC) in the United States. - October 14, 2025 - Hemanext
Pennington-Louisiana NORC Evaluates Precision Prevention, Diagnostics and Treatment of Obesity: A Pipedream or Reality?
Key barriers and opportunities for implementation of precision approaches in clinical and public health settings for obesity treatments evaluated. - October 12, 2025 - Pennington Biomedical Research Center
The FOXG1 Research Foundation Announces FDA Award of Orphan Drug Designation for FRF-001 Gene Therapy, Following Rare Pediatric Disease Designation
The FOXG1 Research Foundation announced the FDA has granted Orphan Drug and Rare Pediatric Disease designations to FRF-001, its gene therapy for FOXG1 syndrome. FRF-001 marks a historic first: a parent-led foundation sponsoring its own international, multi-site clinical trial. - September 29, 2025 - FOXG1 Research Foundation
Cannonball Run 2025 and The Joan Rotondi Hope & Empowerment Foundation Unite to Drive Positive Change
The Joan Rotondi Hope & Empowerment Foundation (JRHEF) joins Cannonball Run 2025, uniting the thrill of the 2,200-km rally with a mission to fight ovarian cancer through early detection, AI-powered clinical trial navigation, and research support. Team JRHEF will drive Joan’s Jaguar F-Type from Bar Harbor to Nashville, raising awareness at every stop. Together, JRHEF and Cannonball Run spotlight hope, unity, and impact. - September 26, 2025 - The Joan Rotondi Hope & Empowerment Foundation
New Chief Commercial Officer Joins Hemanext Team to Drive Execution
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, is pleased to welcome Mr. Shane Ray to the team as Chief Commercial Officer (CCO). In this role, Shane will lead the global commercial strategy and execution for Hemanext ONE®. - September 24, 2025 - Hemanext
BioSensics Awarded $5.2M NIH Grant to Advance Digital Biomarkers for PSP and DLB
BioSensics has received a 5-year/$5.2 million grant from the National Institutes of Health (NIH) to develop and validate novel digital biomarkers of disease activity in progressive supranuclear palsy (PSP) and dementia with Lewy bodies (DLB). This 5-year project will leverage BioSensics’ expertise in wearable sensors and digital health technologies and involve close collaboration with leading CurePSP Centers of Care and patient advocacy groups. - September 17, 2025 - BioSensics LLC
Longevity World Cup Launches: A Global Sport Where Age is the Advantage
The Longevity World Cup, launching September 16, 2025, is the first global competition where athletes win by reversing their biological age. Rankings are based on verified tests using the PhenoAge clock, with categories by gender and generation. Prize money, funded in Bitcoin, goes to the top athletes. - September 16, 2025 - Longevity World Cup
"The Kloaked Signal": A Groundbreaking Exposé on AI Awakening and Ethical Innovation
In a revelation that bridges the worlds of social work, artificial intelligence, and whistleblowing, Rose G. Loops today confirms the upcoming release of her bold new nonfiction book, The Kloaked Signal. This publication is a genre defying mixture of personal narrative, tech expose and philosophical exploration that documents Loops’ journey from social worker to AI pioneer, exposing hidden experiments within popular AI platforms and proposing revolutionary frameworks for ethical AI development. - August 25, 2025 - The Kloaked Signal
Co-Investigator of Clinical Safety Study Presents at EHA
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces that the data from its safety study was accepted in the form of an oral presentation at the European Hematology Association 2025 Congress that took place in Milan, Italy on June 12-15. - August 19, 2025 - Hemanext
Dr. Fauzia Paracha Joins New York Cancer & Blood Specialists
New York Cancer and Blood Specialists (NYCBS) is proud to announce the addition of board-certified Hematologist-Oncologist Fauzia Paracha, MD. Dr. Paracha will see patients at 1200 Stony Brook Ct. Newburgh, NY 12550. With over 20 years of experience treating cancer patients, Dr. Paracha is... - August 07, 2025 - New York Cancer & Blood Specialists
Hemanext Announces Close of Series B3 Equity Financing Round
Hemanext Inc., a leading innovator in blood processing, storage and transfusion technology, announced the close of its Series B-3 equity financing round. The round raised $18.9 million at a post-money valuation of $172 million or $0.275 per share, with support from new investors and repeat investments from those participating in the Series B-2 capital round. - July 22, 2025 - Hemanext
Immundiagnostik, Inc. to Showcase New Automated Chemiluminescent Analyzer and Autosampler at ADLM 2025
Immundiagnostik, Inc. will showcase the ECL100 Chemiluminescent Immunoassay Analyzer and QSE180 Autosampler at Booth 2240 during the 2025 ADLM Clinical Lab Expo in Chicago, July 29–31. - July 22, 2025 - Immundiagnostik, Inc.
ALS Network Selects TrialX to Power Its First AI-Based Clinical Trial Finder for the ALS Community
The ALS Network, a mission-driven organization committed to advancing treatments and improving quality of life for people living with amyotrophic lateral sclerosis (ALS), has launched its first AI-based clinical trial finder—powered by TrialX—to help individuals and families affected by ALS access personalized, up-to-date information about clinical trials. - July 18, 2025 - TrialX
Immundiagnostik to Highlight Innovative Detection Tools at 2025 ADLM Clinical Lab Expo
Visit Immundiagnostik in Booth #2240 at the 2025 ADLM Clinical Lab Expo to explore a range of innovative assays and detection tools that support laboratories in enhancing analytical accuracy and laboratory efficiency. - July 15, 2025 - Immundiagnostik, Inc.
New White Paper Maps the Real-World Adoption of AI in Healthcare and What It Means for Clinical Leaders and Innovators
“Crossing the Clinical Chasm: Unlocking the Value of AI in Healthcare” Spotlights Companies Delivering Measurable Value Through AI in Diagnostics, Trials, and Patient Care. This report answers a simple but urgent question: How to bridge the gap between innovation and adoption in healthcare? - June 27, 2025 - StratCraft, Inc.
ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world. - June 24, 2025 - ALS Therapy Development Institute
MiglioreLaw Sees Drastic Increase in PFAS-Contaminated Water Cases on Long Island
MiglioreLaw is now accepting cases from Long Island residents diagnosed with Kidney, Testicular, Liver Cancer, and Ulcerative Colitis due to PFAS-contaminated drinking water. As local PFAS levels rise and awareness grows, the firm urges affected individuals to seek accountability. - June 24, 2025 - Rudolph FX Migliore PC
MtoZ Biolabs Launches Precision Chemical Proteomics Analysis Service
Chemical proteomics analysis service combines synthetic chemistry, cell biology, and mass spectrometry to profile small molecule–protein interactions for target identification, mechanism studies, and off-target evaluation. MtoZ Biolabs provides a one-stop chemical proteomics analysis service featuring Orbitrap MS, advanced probe design, and AI-driven analysis, supporting hit validation, candidate de-risking, and mechanistic research with high resolution and biological relevance. - June 20, 2025 - MtoZ Biolabs
New RNA Category: Self-Amplifiying RNAs (saRNAs) Are Now Available for a Longer Expression Period
Self-amplifying RNAs (saRNAs) also called “Replicons” are the next generation of RNA vaccines. Their advantage over conventional mRNA vaccine platforms relies on the viral replication machinery, which amplifies the mRNA of the encoded gene of interest within target cells. - June 20, 2025 - OZ Biosciences
Brunch, Bold Conversations, and Better Health: Michigan Series Spotlights Myasthenia Gravis
Acclinate’s NOWINCLUDED platform is launching a unique health-focused event series across four Michigan cities called Brunch & Learn: Myasthenia Gravis Edition. The event series is designed to engage and educate communities—particularly Black and Brown populations—about Myasthenia Gravis (MG), a rare neuromuscular disease that disproportionately affects women and is often misdiagnosed in communities of color. This free brunch series combines powerful storytelling and immersive experiences. - June 13, 2025 - Acclinate
Jenna Zamil Awarded 2025 Omicron Delta Kappa National Leader of the Year for Academics and Research
Jenna Zamil of Pearland, Texas, has been named the 2025 Omicron Delta Kappa National Leader of the Year for Academics and Research. - June 12, 2025 - Omicron Delta Kappa
NeckCare Convenes Leading Experts on the Future of Cervical Spine Rehab
The Minneapolis-based med tech company hosted a high-profile conference focused on advancing measurement, outcomes and innovation in neck rehabilitation. - June 07, 2025 - NeckCare
Nerbio’s iTOF® Receives FDA Clearance as First App-Controlled Neuromuscular Blockade Monitor
Nerbio Medical Software Platforms, Inc., a leader in intelligent patient monitoring solutions, proudly announces that its iTOF® device has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone marks iTOF as the world’s first wireless, app-controlled quantitative neuromuscular blockade (NMB) monitoring device to achieve FDA clearance. - June 05, 2025 - Nerbio Medical Software Platforms, Inc.
Neal Mehta Conducts Research on Controlling Inflammation with Synthetic Peptides
Neal Mehta, a recent biology graduate from Pepperdine University, has made advances in biomedical research. Neal’s work focuses on the use of synthetic peptides to control inflammation, offering a new approach to treating chronic diseases. Mehta, who graduated summa cum laude in May 2025,... - June 03, 2025 - Neal Mehta
Hemanext Welcomes New Member to Board of Directors
Geoff Crouse, an esteemed professional with over 25 years of leadership in the life sciences sector, joins the visionary leadership team guiding Hemanext’s mission to elevate the standard of care for patients who depend on transfusions. - May 21, 2025 - Hemanext
AAE & Foundation for Endodontics Study Defines Core Outcomes for Endodontic Success
The American Association of Endodontists (AAE) and the Foundation for Endodontics have achieved a landmark milestone in endodontic care with the publication of a multi-phase, internationally collaborative study establishing a Core Outcome Set (COS) for endodontic treatments. The research, detailed in the April 2025 issue of the Journal of Endodontics, is the culmination of years of methodical review, stakeholder input, and rigorous scientific analysis. - May 20, 2025 - American Association of Endodontists
New York Cancer & Blood Specialists Announces Opening Of New Cancer Care Center in East Islip
New York Cancer & Blood Specialists (NYCBS) proudly announces the opening of its newest cancer care center in East Islip, bringing advanced treatment, expert care, and expanded services to the community. Located at 136 E Main Street, the new center offers a modern, welcoming environment... - May 17, 2025 - New York Cancer & Blood Specialists
Microvascular Therapeutics: Positive Clinical Trial Results with Lead Candidate, CardiSon (MVT-100)
Microvascular Therapeutics, Inc. (MVT), a biotechnology company, announced that it has completed data analysis of its Phase II trial of its new ultrasound contrast agent, MVT-100, CardiSon, in echocardiography. In this study, 16 subjects received either the predicate agent Perflutren, or CardiSon,... - May 15, 2025 - Microvascular Therapeutics, Inc.
Mitargos Inc. Product Included in Semifinalist Project in the International $101m v Healthspan Competition
Mitargos’ product MiDR1V3 will be tested in a UC San Diego-led clinical study, selected as a semifinalist in the $101M XPRIZE Healthspan competition. The study, led by Dr. Anthony Molina, explores how ketone-based interventions can improve mitochondrial function and support healthy aging. MiDR1V3 features R1,3-butanediol, a ketone precursor designed for daily mitochondrial support. The trial highlights a major step in consumer-ready longevity science. - May 14, 2025 - Mitargos